Page 10 - Pharma

Govt drops import duty on remdesivir ingredient, injections for Covid-19

Remdesivir is being used to treat Covid-19 patients, jacking up its demand.

World's largest vaccine maker India tees up global blitz to contain virus

India manufactures more than 60% of all vaccines sold across the globe

Practo's telemedicine subscription plans record 250% growth in 6 months

Most of the health plan users are from metro cities like Delhi, Bengaluru, and Mumbai

Juggat Pharma to set up 2 plants in FY22 to boost nutraceutical production

Its flagship product Mulmina, an antioxidant-rich immune boosting drink, has seen traction of over 150 per cent since April.

Lupin: Q2 unimpressive, more triggers required to drive stock

US growth has picked up as anticipated, but India and a few other markets still lag

With US sales recovering, Lupin Q2 profit up 97% over Q1 to Rs 211 cr

The revenues, however, dropped by 1.2 percent on a year on year (YoY) basis to Rs 3,835 crore, but sequentially the revenues rose 8.7 percent

We have an opportunity to replace China as global AC exporter: Blue Star MD

Blue Star's Managing Director B Thiagarajan spoke to T E Narasimhan on how sales are expected to touch pre-Covid-19 levels during festival time and there are chances it may increase by 10 per cent

Nigerian regulator blacklists Vadodara firm over substandard drugs

Matter relates to eight batches of drug made by Mars Remedies from for a Nigerian pharma company; all its products are now barred from entry into African nation

Cardiac, vitamin drugs see pharma sales rebound with 4.5% growth in Sept

Industry says fresh prescriptions are picking up

Higher sales in domestic market, lower costs bode well for Glenmark

The other trigger for the stock is the cost savings from lower investments in R&D and fund raising for innovation research

Kochi firm gets nod to test India's first novel molecule for Covid-19

PNB Vesper's drug developed from 12 years of research for small-cell lung cancer (for which it is under trial) has shown positive response in Covid-19, the firm claims

AstraZeneca Pharma India Q1 net profit declines 13 pc at Rs 18.63 cr

Drug firm AstraZeneca Pharma India on Monday reported a 13.38 per centdecline in its net profit to Rs 18.63 crore for the quarter ended June. The company had posted a net profit of Rs 21.51 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a BSE filing. Revenue from operations stood at Rs 193.57 crore for the quarter under consideration. It was Rs 204.56 crore for the same periodyear ago, it added. The board of directors has declared an interim dividend of Rs 2 per equity share for the financial year 2020-21, the filing said. Shares ofAstraZeneca Pharma India were trading at Rs3,381.65per scrip on BSE, up 1.50 per cent over previous close.

Unichem gets USFDA nod for generic version of tolterodine tartrate tablets

The tolterodine tartrate tablets are generic versions of Pfizer Inc's DETROL tablets

Why are cheaper Covid-19 drugs not being promoted, asks Parliamentary panel

Cutting across party lines, the committee members questioned why expensive medicines were often being recommended for Covid-19 treatment

India's Sovereign Pharma dispatches first batch of remdesivir to Cipla

Privately held Sovereign Pharma is manufacturing and packaging Cipla's remdesivir version

First Covid-19 vaccine to reach phase-1 trial is safe, say researchers

Several teams across the world are in a race to develop a vaccine for coronavirus infection

Coronavirus: Eli Lilly starts testing; Gilead drug shows positive signs

Lilly said it currently does not anticipate shortages for any of its medicines, including baricitinib

Glenmark gets tentative nod from USFDA for generic type-2 diabetes tablets

The product is a generic version of AstraZeneca AB's Farxiga tablets

Here's how common mental shortcuts can cause major physician errors

In health care, unconscious biases can lead to disparate treatment of patients and can affect whether similar patients live or die

Govt asks pharma groups to ensure companies follow ethical practices

The DoP drafted the UCPMP has been voluntarily followed by drug firms since 2015., however, the code is not mandatory